Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations for Performing Level-2 Centiloid Transformations for Amyloid PET SUVR values.

Scientific reports·2018
Same author

White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease.

PloS one·2018
Same author

Amyloid-β - a reflection of risk or a preclinical marker?

Nature reviews. Neurology·2018
Same author

Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.

JAMA neurology·2018
Same author

The association of mid-to late-life systemic inflammation with white matter structure in older adults: The Atherosclerosis Risk in Communities Study.

Neurobiology of aging·2018
Same author

White Matter Reference Region in PET Studies of <sup>11</sup>C-Pittsburgh Compound B Uptake: Effects of Age and Amyloid-β Deposition.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2018

Related Experiment Video

Updated: May 24, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Imaging measures predict progression in progressive supranuclear palsy.

Jennifer L Whitwell1, Jia Xu, Jay Mandrekar

  • 1Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA. whitwell.jennifer@mayo.edu

Movement Disorders : Official Journal of the Movement Disorder Society
|March 15, 2012
PubMed
Summary
This summary is machine-generated.

Neuroimaging can predict clinical progression in progressive supranuclear palsy (PSP). Specific MRI measures, like superior cerebellar peduncle fractional anisotropy, correlate with PSP rating scale scores, aiding in disease severity assessment.

More Related Videos

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Related Experiment Videos

Last Updated: May 24, 2026

Using Retinal Imaging to Study Dementia
09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

Area of Science:

  • Neuroimaging and Neurological Disorders
  • Quantitative MRI in Neurodegeneration

Background:

  • Progressive supranuclear palsy (PSP) is a neurodegenerative disease with significant disability.
  • Assessing disease severity and predicting progression in PSP is clinically important.
  • The Progressive Supranuclear Palsy Rating Scale (PSPRS) is a key clinical measure.

Purpose of the Study:

  • To investigate the association between neuroanatomical changes and clinical severity in PSP.
  • To determine if imaging markers can predict disease progression as measured by the PSPRS.

Main Methods:

  • 22 subjects with probable PSP underwent serial PSPRS assessments.
  • Structural MRI and diffusion tensor imaging (DTI) were performed.
  • Associations between brain volumes, midbrain area, superior cerebellar peduncle (SCP) fractional anisotropy (FA), and PSPRS scores (baseline and change) were analyzed.

Main Results:

  • SCP fractional anisotropy showed significant correlations with the total PSPRS score and the gait/midline subscore.
  • Whole brain volume, midbrain area, and disease duration were predictive of changes in the gait/midline subscore over time.
  • These findings suggest a link between specific structural brain changes and clinical decline in PSP.

Conclusions:

  • Neuroimaging markers, particularly SCP fractional anisotropy, are associated with clinical measures of disease severity in PSP.
  • Brain imaging metrics hold potential for predicting clinical progression in patients with progressive supranuclear palsy.
  • These findings support the use of quantitative imaging in monitoring PSP and potentially evaluating therapeutic interventions.